Braeburn’s New Drug Application for our long-acting weekly and monthly buprenorphine formulations (CAM2038) is currently under review by the FDA. A priority review designation has previously been granted for this application. If approved, CAM2038 will be marketed in the U.S., under a licensing agreement with Camurus, in a range of dosage strengths for once weekly and once monthly subcutaneous injection.
Braeburn is also investigating CAM2038 in opioid tolerant patients with chronic pain as part of its ongoing pivotal Phase III program.
Learn more about the results of CAM2038’s clinical trials.
Braeburn is committed to supporting independent scientific research and independent medical education for the
advancement of medical and scientific understanding in our therapeutic areas of interest.
Please note that Braeburn will not provide grant support for the following:
– Independent Medical Educational Grants directed to individuals
– Grants to support personal travel, travel fellowships or entertainment activities
– Grants for rewards or recognition
Note that no additional requests will be considered for 2018. Please check back again at a later date.